Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00687492
First received: May 28, 2008
Last updated: December 1, 2010
Last verified: December 2010
  Purpose

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.


Condition
Hypercholesterolemia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
  • The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]
  • The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. [ Time Frame: After collecting all Patient Record Form. ] [ Designated as safety issue: No ]

Estimated Enrollment: 8000
Study Start Date: May 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients had to be on a lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Criteria

Inclusion Criteria:

  • 2 or more risk factors (according to NCEP ATP III guideline)
  • Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion Criteria:

  • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study.
  • Participation in a clinical study during the last 90 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00687492

  Show 59 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Park Jeong Euy Sungkyunkwan University School of Medicine
  More Information

No publications provided

Responsible Party: Joher Raniwalla, AstraZeneca
ClinicalTrials.gov Identifier: NCT00687492     History of Changes
Other Study ID Numbers: NIS-CAP-DUM-2008/1
Study First Received: May 28, 2008
Last Updated: December 1, 2010
Health Authority: Philippines: Bureau of Food and Drugs

Keywords provided by AstraZeneca:
hypercholesterolemia
NCEP ATP III guidelines
survey

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 30, 2014